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Carbapenems are administered as the ﬁnal drug of choice for treating compli-
cated nosocomial infections caused by multidrug-resistant Acinetobacter baumannii
strains. It is currently a worldwide issue that metallo-β-lactamases (MBLs) as
carbapenem-hydrolyzing enzymes are one of the major drug resistance mechanisms.
This investigation is thus aimed to assess the prevalence and characterize the
MBL-producing strains of A. baumannii both by phenotypic assays and by genotypic
characterization. A total of 73 isolates of A. baumannii were phenotypically and
genotypically characterized from patients (N= 1,000) with severe urinary tract
infection. Tested strains were subjected to double disc synergy testing (DDST) by
Kirby–Bauer disc diffusion method with imipenem (IMP) and IMP/EDTA combina-
tion discs. Plasmid DNA was molecularly screened for MBL-encoding blaIMP, blaVIM,
blaGIM, and blaNDM genes by PCR for the genetic relatedness of the MBL genes with
carbapenem resistance. Carbapenem resistance proﬁle showed 100%, 45%, and 49%
non-susceptibility against imipenem, doripenem, and meropenem, respectively.
Altogether 42.46% (n= 31) of the isolates showed MBL production upon double
disc phenotypic test with IMP and IMP/EDTA discs. The blaVIM and blaGIM were
detected in 34.24% (n= 25) and 16.43% (n= 12) of the isolates, respectively, while the
co-occurrence of blaVIM and blaGIM was 2.73% among the isolates. DDST-positive
isolates showed 21.19% and 9.58% strains positive for blaVIM and blaGIM, respectively,
whereas 1.36% of the strains for both genes. None of the strains yielded blaIMP and
blaNDM genes. The ﬁndings of this study showed prevalence of carbapenem resistance
among A. baumannii from urine samples and the frequency of blaVIM and blaGIM.
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Introduction
Acinetobacter baumannii, a pleomorphic, aerobic Gram-negative bacterium,
has emerged as one of the critical multidrug-resistant nosocomial pathogens
worldwide [1]. A. baumannii is considered as one among the top seven pathogens
threatening the patient’s healthcare and as an unmet medical need [2].
A. baumannii infections are considered with great concern due to their resistance
pattern exhibited to several classes of antibiotics, especially carbapenems [3] and
are considered as sentinels of drug resistance with the designation as carbapenem-
resistant A. baumannii [4]. Among several mechanisms related to carbapenem
resistance, the resistance exhibited due to carbapenem-hydrolyzing enzymes is
frequently considered worldwide [5]. Based on the Ambler classiﬁcation, these
enzymes belong to class B metallo-β-lactamase (MBL) and class D OXA-type
carbapenemases and most of them are mediated by plasmids [6].
MBLs are further classiﬁed into several families with blaVIM, blaIMP,
blaGIM, and more recently blaNDM and are located in the gene cassettes of class
1 integrons with blaIMP in class 3 integrons [7, 8]. For the optimal MBL activity,
divalent cations are required as cofactors with further action of one or two zinc
ions for their catalytic activity with chelators as inhibitory agents [9]. These MBLs
are highly potent in hydrolyzing all the β-lactam antibiotics except the
monobactams such as aztreonam [10] and there are no known MBL inhibitors
[11]. Dissemination of MBL-encoding genes is highly popular among the
plasmids or by integron-borne mobile gene cassettes through horizontal gene
transfer mechanisms [12]. As a dominant MBL variant, blaNDM [13] and blaVIM-2
[14] have recently emerged with worldwide reports.
Earlier studies have reported the emergence of blaVIM-, blaIMP-, and blaGIM-
based carbapenem resistance among A. baumannii [15, 16] along with the
increased incidences of blaNDM-based resistance [17, 18]. Detection of these
MBLs is often based on the inhibitor-based test using metal ion chelators, such as
ethylene diamine tetra acetic acid (EDTA) or thio-based compounds [19]. Among
several phenotypic detections, Clinical Laboratory Standards Institute (CLSI) [21]
advocates the application of modiﬁed Hodge’s test, CarbaNP test, and/or a
molecular-based assay for the conﬁrmation of the MBL producers among
Enterobacteriaceae and A. baumannii strains. Genotypic characterization of the
MBL-based genetic determinants blaVIM, blaIMP, blaGIM, and blaNDM is detected
by polymerase chain reactions (PCRs) and clonal relatedness is analyzed by
various molecular methods [20].
With this background, the present investigation aimed to phenotypically and
genotypically characterize the MBL producers among A. baumannii strains with
the phylogenetic assessment of the MBL-based genetic determinants such as
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blaVIM, blaIMP, blaGIM, and blaNDM screened from the patients with severe urinary
tract infections from South India.
Materials and Methods
Study design
A total of 73 consecutive and non-repetitive A. baumannii isolates, which
were isolated and identiﬁed for a period of 12 months (2014–2015) from urine
samples of patients with severe urinary tract infections (N= 1,000), were pheno-
typically and genotypically conﬁrmed by conventional microbiological analytical
tests and PCR, respectively, at the Department of Microbiology. These character-
ized strains were subjected to antibiotic susceptibility test by standard Kirby–
Bauer disc diffusion method using imipenem (IMP; 10 μg), doripenem (10 μg),
and meropenem (10 μg) for the carbapenem resistance proﬁle of the selected
strains under study.
Phenotypic conﬁrmatory test
With the observation and record of the carbapenem resistance, all the strains
were further subjected for phenotypic double disc synergy testing (DDST) as per
the CLSI (2012) [21]. All the test strains were prepared as fresh broth cultures and
lawn was made onto sterile Mueller–Hinton agar (MHA; Hi-Media, Mumbai). For
the MBL detection, two discs were used for the proﬁle such as IMP (10 μg)
(Hi-Media) and IMP/EDTA. An amount of 0.5 M EDTA was prepared by
dissolving 186.1 g of disodium EDTA-2H2O in 1,000 ml of distilled water
(pH 8.0) and was sterilized by autoclaving. An amount of 10 μl was added onto
one of the IMP discs to obtain the desired concentration of IMP/EDTA
(10/750 μg). The discs were placed onto the surface of the MHA at a distance
of 20 mm from each. The plates were then incubated for a period of 24 h at 37 °C.
The increase in zone size of ≥7 mm around the IMP/EDTA disc than IMP was
interpreted as MBL producers.
Molecular detection of blaVIM, blaIMP, blaGIM, and blaNDM genetic determinants in
MBL producers
Extraction of plasmid DNA and PCR ampliﬁcation. All the strains were stored at
−80 °C in 80%/20% (v/v) glycerol in Luria–Bertani media for genetic stability of
MBL-MEDIATED CARBAPENEM RESISTANCE IN ACINETOBACTER BAUMANNII 541
Acta Microbiologica et Immunologica Hungarica 65, 2018
resistance upon storage [22]. Plasmid DNA was extracted from fresh cultures of A.
baumannii using Qiagen extraction kit in accordance with the manufacturer’s
instructions and was stored in −20 °C until further use. An amount of 15 μl of
ampliﬁcation reaction mixtures was prepared by mixing 7.8 μl of 2× Master Mix
(Takara, Japan) in 5.6 μl of double distilled water. Speciﬁc forward primer and
reverse primer (Euroﬁns Genomic India Pvt Ltd., Bangalore, India) of blaVIM,
blaIMP, blaGIM, and blaNDM were added using the standard PCR conditions
(Table I). PCR ampliﬁcation was carried out and the resulting PCR amplicons
were examined in 1% agarose gel electrophoresis containing ethidium bromide,
which was visualized in a gel documentation system. The 100 bp DNA ladder was
used to conﬁrm the amplicon size.
Results
Preliminary screening for the carbapenem resistance tests showed 100%,
45%, and 49% non-susceptibility against imipenem, doripenem, and meropenem,
respectively, as per CLSI zone interpretative criteria (Figure 1). DDST with IMP
and IMP/EDTA discs yielded 42.46% (n= 31) of the isolates as MBL producers
(Table II). A total of 37 isolates (50.68%) showed resistance to all the carbape-
nems tested with 31.50% (n= 23) DDST-positive (Figure 2).
Genotypic characterization of the MBL genetic determinants showed the
presence of blaVIM and blaGIM in 34.24% (n= 25) and 16.43% (n= 12) of the
isolates. Co-occurrence of blaVIM and blaGIM was observed in 2.73% (n= 2) of
the isolates. DDST-positive isolates showed 21.19% (n= 16) positive for blaVIM
and 9.58% (n= 7) positive for blaGIM determinants (Table III and Figure 3).
Among the two isolates with both blaVIM and blaGIM genes, only one strain was
DDST-positive. However, none of the strains yielded blaIMP and blaNDM genes.
Discussion
Awide range of nosocomial infections encompassing meningitis, septicemia,
pneumonia, and skin and wound infections are caused by A. baumannii and are
considered as a major challenge in the patient healthcare [23]. Carbapenems such as
imipenem, doripenem, meropenem, and ertapenem are considered as the last resort
antibiotics in the treatment of severe and complicated infections established by
multidrug-resistant A. baumannii [24]. In recent decades, resistance to carbapenems
is highly reported [25]. The present investigation has also recorded a total of
37 isolates (N= 73) as carbapenem-resistant strains. All the strains fall under the
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Figure 1. Frequency of resistance exhibited by A. baumannii toward the antibiotics tested
Table II. Preliminary screening and phenotypic conﬁrmation of ESBL producers among the A. baumannii
isolates as per CLSI (2012) [21]
Isolate Preliminary screening DDST
A. baumannii
(N= 73)
100%
(n= 73)
Antibiotics Positive (%)
Imipenem and
imipenem+ EDTA
41.46
(n= 31)
Note: ESBL: extended-spectrum β-lactamase; DDST: double disc synergy test; EDTA: ethylene diamine
tetra acetic acid; CLSI: Clinical Laboratory Standards Institute.
Figure 2. The speciﬁcity of detection methods employed for identifying drug-resistant strains
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imipenem-resistant strains of A. baumannii. One hundred percent of the strains
showing imipenem resistance are also reported in an earlier study from South India
[27]. Imipenem showing intrinsic resistance in A. baumannii is reported [28] and in
many earlier studies the isolates of A. baumannii for carbapenemase and MBL
production were categorized based on imipenem susceptibility and resistance
patterns [29]. Several studies have recorded the higher incidences of imipenem
non-susceptibility/resistance [30, 31]. This study has recorded nearly 60%–65% of
non-susceptibility against doripenem and meropenem with only 15.06% and
13.69% susceptibility against the same, respectively. Similar observations were
recorded from Turkey with 66.6% resistance against meropenem and 49.9%
against doripenem [32]. Another study from USA showed 68% and 80% non-
susceptibility to meropenem and doripenem, respectively [33]. On the contrary, an
earlier study from Punjab recorded only 6% of the isolates to exhibit non-
susceptibility against doripenem and meropenem [34]. Along with these routinely
administered carbapenems, administration of ertapenem induced no impact on the
susceptibility pattern of imipenem and was directly associated with the reduced use
of imipenem and ciproﬂoxacin among A. baumannii [35]. However, this study
Table III. Distribution of blaIMP, blaNDM, blaVIM, and blaGIM genes among the MBL producers of
A. baumannii
MBL-positive
isolates Target genes studied (%)
A. baumannii
(N= 73)
blaIMP blaNDM blaVIM blaGIM blaVIM+ blaGIM
0 0 34.24
(n= 25)
16.43
(n= 12)
2.73
(n= 2)
Note: MBL: metallo-β-lactamase.
Figure 3. Electrophoretogram of (a) blaVIM gene and (b) blaGIM amplicons run along with 100 bp
DNA ladder (Lane 1)
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limits per se the omission of ertapenem under carbapenem-resistant proﬁle for the
test organisms under the study.
Phenotypic detection of MBL production was observed using IMP and IMP/
EDTA potentiation disc test. Among the tested isolates, with 100% resistance
against imipenem and nearly 63% resistance against doripenem and meropenem,
phenotypic conﬁrmation was achieved only in 42.46% of the isolates. In addition,
DDST positivity co-related only with 31.50% (n= 23) of the isolates conﬁrmed by
Kirby–Bauer diffusion assay. Among the 73 imipenem-resistant isolates, only 31
were DDST-positive, which might be due to the blaIMP gene cassettes associated
with integrons that do not phenotypically express the blaIMP type of genetic
determinants [36]. About 21.91% and 9.58% of the isolates among 31 DDST-
positive A. baumannii, expressing blaVIM and blaGIM, suggest the role of VIM- and
GIM-type β-lactamases in inducing carbapenem resistance. Although variants of
IMP and VIM are frequently reported, MBL genetic determinants can be restricted
to certain geographical regions with members of SPM, GIM, and SIM variants [37].
Genotypic characterization of MBL determinants with phenotypic-positive DDST
showing 6 and 19 negative isolates may be again related to the variants exhi-
bited among class I integron structures, which are frequently detected among
A. baumannii [38, 39]. Comparative analysis between phenotypic and genotypic
data observed in the present investigation suggests DDST to be highly reliable and
easy to perform for the preliminary screening of MBL production with the reports
varying from 7.5% [40] to 70.9% [27].
Molecular detection of the genetic determinants of MBL production such as
blaVIM, blaIMP, blaGIM, and blaNDM was observed using PCR. All the imipenem-
resistant isolates (n= 73) of A. baumannii showed blaIMP and blaNDM negative. In
comparison with the carbapenem-resistant proﬁle (imipenem – 100%, doripenem –
61.64%, and meropenem – 67.12%) and DDST-positive isolates (n= 31), only 25
(34.24%) and 12 (16.43%) showed the presence of blaVIM and blaGIM. This variation
might be due to the other non-enzymatic mechanisms, such as presence of efﬂux
pumps, role of outer membrane proteins etc., exhibiting the carbapenem resistance
property among A. baumannii [41]. A widespread distribution of MBL producers
among A. baumannii is observed worldwide such as 70%–90% in India, 27.1% in
Pakistan, and considerable numbers in Europe, Australia, and Africa [42, 43].
Among the MBL genetic determinant, co-occurrences of the genes are also
not uncommon. The studies record the different patterns of co-occurring MBL
genes from different countries [44]. In view with this, the present study also
records the co-occurrence of blaVIM and blaGIM in two isolates (2.73%). Com-
parative analysis between phenotypic and genotypic detection also shows a
signiﬁcant report. The study records 21.91% (n= 16) and 9.58% (n= 7) with
DDST+ blaVIM and DDST+ blaGIM positivity, respectively, with one 1.36% of
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the isolate showing DDST+ blaVIM+ blaGIM positivity. In an earlier study from
Nepal, co-existence of blaOXA-23 and blaNDM-1 was detected [45] with the
presence of other class B MBLs, such as blaVIM and blaGIM. One of the recent
studies showed the presence of blaVIM only in imipenem-resistant genomic species
of 13TU – A. baumannii and not in other isolates [46]. These results when
compared with the present investigation vividly portray the differences in the
phenotypic and genotypic traits against the carbapenems among the A. baumannii
species existing in different geographic locale.
A. baumannii traits acquire different kinds of antimicrobial resistance and
are emerging as a dreadful nosocomial pathogen leading to complications in the
treatment and control. Frequency of MBLs and the distribution of their genetic
determinants restrict the administration of carbapenems against A. baumannii.
Thus, this study concludes by stating the need for the proper and periodical
antimicrobial surveillance programs for using carbapenems against A. baumannii
isolates, as there exists a variation in the resistance pattern and the associated genes
in inducing the carbapenemase resistance.
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